Sandoz Will Appeal Against US Enbrel Patent Setback
Sandoz expects to bring an expedited appeal against a US district court’s finding that two patents protecting Amgen’s Enbrel etanercept brand until 2028 and 2029 are valid.
You may also be interested in...
Sandoz had hinted that further legal action was viable as it looks to introduce biosimilar competition to Amgen’s Enbrel blockbuster in the US. The Novartis subsidiary has now taken its fight to the very highest court.
Sandoz has failed to overturn on appeal an invalidity ruling for two patents covering Enbrel in the US, barring a path to market for its Erelzi biosimilar, potentially until patent expiry in 2029.
In the month ahead, Mylan and Upjohn will at last begin to make final preparations for their proposed combination while second-quarter results are expected from large cap companies including Novartis’ Sandoz, Amgen, Biogen and Pfizer.